• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国腹部放射学会肝癌诊断疾病聚焦专家组关于 CT 和 MRI 的 LI-RADS v2018 白皮书。

White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI.

机构信息

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.

Department of Radiology, University of Toronto, Toronto, ON, Canada.

出版信息

Abdom Radiol (NY). 2018 Oct;43(10):2625-2642. doi: 10.1007/s00261-018-1744-4.

DOI:10.1007/s00261-018-1744-4
PMID:30155697
Abstract

The Liver Imaging and Reporting Data System (LI-RADS) is a comprehensive system for standardizing the terminology, technique, interpretation, reporting, and data collection of liver imaging with the overarching goal of improving communication, clinical care, education, and research relating to patients at risk for or diagnosed with hepatocellular carcinoma (HCC). In 2018, the American Association for the Study of Liver Diseases (AASLD) integrated LI-RADS into its clinical practice guidance for the imaging-based diagnosis of HCC. The harmonization between the AASLD and LI-RADS diagnostic imaging criteria required minor modifications to the recently released LI-RADS v2017 guidelines, necessitating a LI-RADS v2018 update. This article provides an overview of the key changes included in LI-RADS v2018 as well as a look at the LI-RADS v2018 diagnostic algorithm and criteria, technical recommendations, and management suggestions. Substantive changes in LI-RADS v2018 are the removal of the requirement for visibility on antecedent surveillance ultrasound for LI-RADS 5 (LR-5) categorization of 10-19 mm observations with nonrim arterial phase hyper-enhancement and nonperipheral "washout", and adoption of the Organ Procurement and Transplantation Network definition of threshold growth (≥ 50% size increase of a mass in ≤ 6 months). Nomenclatural changes in LI-RADS v2018 are the removal of -us and -g as LR-5 qualifiers.

摘要

肝脏影像报告和数据系统 (LI-RADS) 是一个用于规范肝脏影像学术语、技术、解读、报告和数据收集的综合系统,其总体目标是改善与肝细胞癌 (HCC) 风险患者或确诊患者相关的沟通、临床护理、教育和研究。2018 年,美国肝病研究学会 (AASLD) 将 LI-RADS 纳入其 HCC 影像学诊断的临床实践指南。为了使 AASLD 和 LI-RADS 诊断影像学标准相协调,LI-RADS v2017 指南需要进行微小修改,因此需要进行 LI-RADS v2018 更新。本文概述了 LI-RADS v2018 中包含的主要变化,并介绍了 LI-RADS v2018 诊断算法和标准、技术建议和管理建议。LI-RADS v2018 的实质性变化包括删除了在先前监测性超声上可见的要求,用于非边缘动脉期高增强和非周边“洗脱”的 10-19mm 观察的 LR-5 分类,以及采用器官获取和移植网络对阈值生长的定义(在≤6 个月内质量增加≥50%)。LI-RADS v2018 的命名变化包括删除了-LR-5 qualifier 中的 -us 和 -g。

相似文献

1
White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI.美国腹部放射学会肝癌诊断疾病聚焦专家组关于 CT 和 MRI 的 LI-RADS v2018 白皮书。
Abdom Radiol (NY). 2018 Oct;43(10):2625-2642. doi: 10.1007/s00261-018-1744-4.
2
Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.基于 LI-RADS v2018 的肝细胞癌的 MRI 诊断性能,与 v2017 相比。
J Magn Reson Imaging. 2019 Sep;50(3):746-755. doi: 10.1002/jmri.26640. Epub 2019 Jan 15.
3
Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.LI-RADS 版本 2018、LI-RADS 版本 2017 和 OPTN 标准用于诊断肝细胞癌的性能比较。
AJR Am J Roentgenol. 2020 Nov;215(5):1085-1092. doi: 10.2214/AJR.20.22772. Epub 2020 Sep 2.
4
Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging.肝脏影像报告和数据系统 2018 年版:对分类和肝细胞癌分期的影响。
Liver Transpl. 2019 Oct;25(10):1488-1502. doi: 10.1002/lt.25614. Epub 2019 Sep 9.
5
LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.LI-RADS 版本 2017 与版本 2018:钆塞酸二钠增强 MRI 诊断肝细胞癌。
Radiology. 2019 Sep;292(3):655-663. doi: 10.1148/radiol.2019182867. Epub 2019 Jul 16.
6
Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.肝细胞癌(HCC)与非 HCC:肝脏影像报告和数据系统 v2018 的准确性和可靠性。
Abdom Radiol (NY). 2019 Jun;44(6):2116-2132. doi: 10.1007/s00261-019-01948-x.
7
What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?临床实践中报告的肝脏影像报告和数据系统(LI-RADS)5类观察结果中,有多大比例不符合LI-RADS 5类标准?
Eur Radiol. 2022 May;32(5):3327-3333. doi: 10.1007/s00330-021-08389-5. Epub 2021 Nov 22.
8
Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.LI-RADS v2018 对除肝细胞癌(HCC)以外的原发性肝癌的评估:LI-RADS 目标人群与无 LI-RADS 定义的 HCC 风险因素患者的比较。
Eur Radiol. 2020 Feb;30(2):996-1007. doi: 10.1007/s00330-019-06448-6. Epub 2019 Oct 25.
9
LI-RADS: Past, Present, and Future, From the Special Series on Radiology Reporting and Data Systems.LI-RADS:过去、现在和未来,来自放射学报告和数据系统特刊。
AJR Am J Roentgenol. 2021 Feb;216(2):295-304. doi: 10.2214/AJR.20.24272. Epub 2020 Dec 23.
10
Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories.肝脏影像报告和数据系统(LI-RADS)v2018:CT/MRI 诊断类别综述。
Can Assoc Radiol J. 2021 Feb;72(1):142-149. doi: 10.1177/0846537119888393. Epub 2020 Jan 24.

引用本文的文献

1
Role of Vascular Liver Diseases in Hepatocellular Carcinoma Development.血管性肝病在肝细胞癌发生中的作用。
Cancers (Basel). 2025 Jun 20;17(13):2060. doi: 10.3390/cancers17132060.
2
Deep learning empowered gadolinium-free contrast-enhanced abbreviated MRI for diagnosing hepatocellular carcinoma.深度学习助力无钆对比增强简化磁共振成像诊断肝细胞癌。
JHEP Rep. 2025 Mar 12;7(5):101392. doi: 10.1016/j.jhepr.2025.101392. eCollection 2025 May.
3
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.
用于评估肝细胞癌患者治疗反应的细胞外囊泡数字评分测定法。
J Exp Clin Cancer Res. 2025 May 1;44(1):136. doi: 10.1186/s13046-025-03379-7.
4
Gadoxetic acid-enhanced MRI for identifying cholangiocyte phenotype hepatocellular carcinoma by interpretable machine learning: individual application of SHAP.钆塞酸增强磁共振成像通过可解释机器学习识别胆管细胞型肝细胞癌:SHAP的个体应用
BMC Cancer. 2025 Apr 28;25(1):788. doi: 10.1186/s12885-025-14147-3.
5
Tumor diameter and enhancing capsule, as well as previous interventional treatments, as potential predictors of vascular lake phenomenon in hepatocellular carcinoma patients treated with drug-eluting beads transarterial chemoembolization.肿瘤直径、强化包膜以及既往介入治疗,作为接受载药微球经动脉化疗栓塞术治疗的肝细胞癌患者出现血管湖现象的潜在预测因素。
J Clin Imaging Sci. 2024 Aug 10;14:29. doi: 10.25259/JCIS_66_2024. eCollection 2024.
6
Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI.非对比性简化磁共振成像在肝脏影像报告和数据系统 LR-3 和 LR-4 观察的患者中用于检测肝细胞癌。
Br J Radiol. 2024 Oct 1;97(1162):1671-1682. doi: 10.1093/bjr/tqae140.
7
Imaging features and management of focal liver lesions.肝脏局灶性病变的影像学特征与管理
World J Radiol. 2024 Jun 28;16(6):139-167. doi: 10.4329/wjr.v16.i6.139.
8
Primary hepatic neuroendocrine neoplasms: imaging characteristics and misdiagnosis analysis.原发性肝脏神经内分泌肿瘤:影像学特征及误诊分析
Front Oncol. 2024 May 14;14:1391663. doi: 10.3389/fonc.2024.1391663. eCollection 2024.
9
HiCCups in management-Pitfalls and pearls for the management of HCC.肝癌管理中的HiCCups——肝癌管理的陷阱与要点
Clin Liver Dis (Hoboken). 2023 May 10;22(3):85-88. doi: 10.1097/CLD.0000000000000041. eCollection 2023 Sep.
10
Focal Liver Lesions in Budd-Chiari Syndrome: Spectrum of Imaging Findings.布加综合征的肝脏局灶性病变:影像学表现谱
Diagnostics (Basel). 2023 Jul 12;13(14):2346. doi: 10.3390/diagnostics13142346.